Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Macon

Showing results (411-420 of 422) with videos related to

Pageof 43
Sort By:
International Journal of Epidemiology|October 13, 2017
Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort StudyJames R Cerhan, Brian K Link, Thomas M Habermann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2014
Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapyMatthew J Maurer, Hervé Ghesquières, Jean-Philippe Jais, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2011
Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphomaMatthew J Maurer, Ivana N M Micallef, James R Cerhan, et al.
Experimental Hematology & Oncology|June 23, 2025
Mitotic MTH1 inhibitor karonudib kills epithelial ovarian cancer independent of platinum sensitivityRachel M Hurley, Jill M Wagner, Arun Kanakkanthara, et al.
American Journal of Hematology|July 29, 2016
Early event status informs subsequent outcome in newly diagnosed follicular lymphomaMatthew J Maurer, Emmanuel Bachy, Hervé Ghesquières, et al.
The American Journal of Cardiology|December 29, 2014
Comparison of outcomes of balloon aortic valvuloplasty plus percutaneous coronary intervention versus percutaneous aortic balloon valvuloplasty alone during the same hospitalization in the United StatesVikas Singh, Nileshkumar J Patel, Apurva O Badheka, et al.
Blood|June 5, 2014
ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomesEdgardo R Parrilla Castellar, Elaine S Jaffe, Jonathan W Said, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2018
Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical TrialsMatthew J Maurer, Hervé Ghesquières, Brian K Link, et al.
Immunity|November 25, 2025
Topography of the HLA-A protein enforces shared and convergent immunodominant B cell and antibody alloresponses in transplant recipientsJohn T Killian, R Glenn King, Aaron C K Lucander, et al.
Biorxiv : the Preprint Server for Biology|April 10, 2023
HLA topography enforces shared and convergent immunodominant B cell and antibody alloresponses in transplant recipientsJohn T Killian, R Glenn King, Aaron C K Lucander, et al.
Pageof 43

Showing results (411-420 of 422) with videos related to

Sort By:
Pageof 43
International Journal of Epidemiology|October 13, 2017
Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort StudyJames R Cerhan, Brian K Link, Thomas M Habermann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2014
Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapyMatthew J Maurer, Hervé Ghesquières, Jean-Philippe Jais, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2011
Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphomaMatthew J Maurer, Ivana N M Micallef, James R Cerhan, et al.
Experimental Hematology & Oncology|June 23, 2025
Mitotic MTH1 inhibitor karonudib kills epithelial ovarian cancer independent of platinum sensitivityRachel M Hurley, Jill M Wagner, Arun Kanakkanthara, et al.
American Journal of Hematology|July 29, 2016
Early event status informs subsequent outcome in newly diagnosed follicular lymphomaMatthew J Maurer, Emmanuel Bachy, Hervé Ghesquières, et al.
The American Journal of Cardiology|December 29, 2014
Comparison of outcomes of balloon aortic valvuloplasty plus percutaneous coronary intervention versus percutaneous aortic balloon valvuloplasty alone during the same hospitalization in the United StatesVikas Singh, Nileshkumar J Patel, Apurva O Badheka, et al.
Blood|June 5, 2014
ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomesEdgardo R Parrilla Castellar, Elaine S Jaffe, Jonathan W Said, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2018
Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical TrialsMatthew J Maurer, Hervé Ghesquières, Brian K Link, et al.
Immunity|November 25, 2025
Topography of the HLA-A protein enforces shared and convergent immunodominant B cell and antibody alloresponses in transplant recipientsJohn T Killian, R Glenn King, Aaron C K Lucander, et al.
Biorxiv : the Preprint Server for Biology|April 10, 2023
HLA topography enforces shared and convergent immunodominant B cell and antibody alloresponses in transplant recipientsJohn T Killian, R Glenn King, Aaron C K Lucander, et al.
Pageof 43